DOLs

Digital

Pharma companies are turning to digital opinion leaders (DOLs) to fight misconceptions, raise disease awareness, and promote their products.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.